CTLA4 and type 1 diabetes mellitus: Two systematic reviews by Lin and colleagues and by de Filette and colleagues found that in clinical practice, the average number of cycles of PD‐1/CTLA‐4 inhibitor combination therapy at the time of T1DM diagnosis is 6.11 cycles (range 1–28 cycles) and 2.7 cycles (range 1–5 cycles), respectively [8, 12].